AORN San Pio
- Address
- Via dell'Angelo 1, 82100 Benevento, Italy
AORN San Pio - Thoracic Oncology Research Center
AORN San Pio is actively engaged in advanced clinical research focusing on thoracic malignancies, particularly in the post-surgical management of lung cancer. The center demonstrates expertise in evaluating novel immunotherapy approaches for patients who have undergone curative surgical resection, contributing to the development of adjuvant treatment strategies that may improve long-term outcomes.
- Non-small cell lung cancer (NSCLC) adjuvant therapy research
- PD-L1 targeted immunotherapy trials in completely resected tumors
- Stage IB-IIIA lung cancer post-operative management
The center participates in international Phase III clinical trials investigating disease-free survival benefits of immunotherapeutic agents in carefully selected patient populations. Their research focuses on patients with specific biomarker profiles, including PD-L1 expression levels and negative EGFR/ALK status, representing a precision medicine approach to adjuvant lung cancer treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in AORN San Pio
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25% | Clinipace Global Limited, Fundacion GECP, Intergroupe Francophone De Cancerologie Thoracique, NVALT-studies Stichting, Queen's University | Phase III | Not Recruiting | Mar 2015 | Mar 2025 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Durvalumab | 2 | Unknown | 2015-03-09 | 2018-07-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.